A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy

To join this study, adults between 18 and 75 years old must have been diagnosed with primary membranous nephropathy through a kidney biopsy. You'd also need to show a certain level of protein in your urine, even after receiving standard care for at least 3 to 6 months.

There are several reasons why someone might not be able to join. For example, if your kidney disease is caused by something else (not primary membranous nephropathy), or if you are pregnant or breastfeeding. You also can't have severe kidney problems requiring dialysis, uncontrolled diabetes, or certain other serious health issues or infections. If you've recently had major surgery or taken certain other medications, you might also not be able to take part.

The study also cannot include individuals who have reduced their protein in the urine by a lot in the last six months (50% or more), or who have a history of recent drug or alcohol abuse. The doctors involved will carefully check all these points to make sure the study is right and safe for you.

If you decide to join this study, you would be assigned to receive either the new medicine (Obinutuzumab) or a standard treatment (tacrolimus). You might also receive other common medications like methylprednisolone, acetaminophen, or diphenhydramine to help manage any potential side effects or for pain relief. The study would involve regular visits to the clinic for check-ups, blood tests, urine tests, and possibly other assessments. These visits are important to monitor your health, how the treatment is working, and to identify any side effects. The total duration of your participation would depend on the study's design, but it will involve ongoing check-ups for a period of time.